Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

23. Dezember 2025 08:45 ET | Quelle: Amplia Therapuetics Limited

Amplia Therapeutics to Present at 2026 ASCO Gastrointestinal Cancers Symposium

Melbourne, Australia, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF) (“Amplia” or the “Company”) is pleased to announce that the Company’s CMO Dr Jason...
19. Dezember 2025 08:45 ET | Quelle: Amplia Therapuetics Limited

Amplia Enters into Second Agreement with Korean Specialist Drug Screening Company Next&Bio to Explore Combination Therapy with FAK Inhibitor and kRAS Inhibitors

HIGHLIGHTS The preclinical research collaboration with specialist drug screening company Next & Bio has been extendedThe collaboration explores the effect of Amplia’s FAK inhibitors in...
12. Dezember 2025 08:45 ET | Quelle: Amplia Therapuetics Limited

Additional Confirmed Response Reported as Part of Amplia Investor Presentation

HIGHLIGHTS An additional confirmed partial response has been recorded in the ongoing ACCENT trialThis brings the confirmed Objective Response Rate to 35%Updated data to be presented at the Life...
03. Dezember 2025 08:45 ET | Quelle: Amplia Therapuetics Limited

Key Narmafotinib Patent Granted in the U.S.

Highlights The Company has received a Certificate of Grant from the US Patent and Trademark Office for a key patent for the FAK inhibitor narmafotinibThe patent extends protection for narmafotinib to...